As families and friends gather for holiday celebrations, respiratory syncytial virus (RSV), also makes its return.

Nirsevimab, a long-acting monoclonal antibody that confers passive immunity for infants up to 6 months old, was approved in ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on safety and side effects.

Respiratory syncytial virus (RSV) caused more than 100,000 deaths in children under age 5 years globally in 2019, according to an analysis published online May 19 in The Lancet. Researchers, led by ...

Heading into the winter respiratory virus season, Kaiser Permanente has begun offering a relatively new vaccine to certain expecting moms to help protect their newborns against respiratory syncytial ...

Peak season ranges from late December to mid-February every year, the CDC website says. Last year in North Carolina, RSV ...

Mississippi has seen more whooping cough cases in 2025 than it has in the previous 16 years. Are flu-like illness rates and RSV visits rising?

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...